drugset / Trial / NCT00031824

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT00031824 ↗

RandomizedSingle-groupDouble-blindSupportive care

Summary

RATIONALE: Hydroxychloroquine may decrease the immune response and be effective in treating chronic graft-versus-host disease. It is not yet known if standard therapy for graft-versus-host disease is more effective with or without hydroxychloroquine. PURPOSE: Randomized phase III trial to compare the effectiveness of standard therapy alone with that of standard therapy plus hydroxychloroquine in treating patients who have newly diagnosed chronic graft-versus-host disease.

Timeline

Start
2002-04
Primary completion
2005-05
Completion
2011-01

Outcome

Missed primary endpoint

paper P = .75 PMID 21689773 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule — Oral
Background Cyclosporine Peptide — Oral
Background Prednisone Other / unclassified — Oral
Background Tacrolimus Small molecule — Oral